Education
About Us
Working with TipRanks
Follow Us
Astellas Pharma (JP:4503)
:4503
Top Page
Astellas Pharma
(OTC:4503)
77Outperform
Positive Factors
Earnings Projections
Future earnings will be the catalysts with projected EPS growth of 37% CAGR 2024-2027.
Growth Trajectory
Padcev's growth acceleration is redefining Astellas's growth trajectory.
Negative Factors
Loss of Exclusivity Impact
Astellas's bottomline should weather Xtandi LOE better than the topline.
Astellas Pharma (4503) vs. S&P 500 (SPY)
Market Cap
¥2.63T
Dividend Yield4.87%
Average Volume (3M)6.96M
Price to Earnings (P/E)51.4
Beta (1Y)0.52
Revenue Growth19.25%
EPS Growth294.48%
CountryJP
Employees14,754
SectorHealthcare
Sector Strength56
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)-54.55
Shares Outstanding1,809,663,100
10 Day Avg. Volume5,297,020
30 Day Avg. Volume6,957,090
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥1,860.67Price Target Upside27.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
Astellas Pharma Business Overview & Revenue Model
Company DescriptionAstellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platform, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694; and collaboration agreement with Cytokinetics, Incorporated. The company has a strategic collaboration and license agreement with Minovia Therapeutics Ltd. for the research, development, and commercialization of cell therapy programs for diseases caused by mitochondrial dysfunction. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.
How the Company Makes MoneyAstellas Pharma generates revenue primarily through the sale of its pharmaceutical products, which include both patented and generic drugs. The company's key revenue streams come from its core therapeutic areas, with oncology and urology products being significant contributors. Astellas invests heavily in research and development to innovate and expand its product pipeline, which helps maintain its competitive edge and market share. Additionally, strategic partnerships and licensing agreements with other pharmaceutical and biotech companies enhance its product offerings and market reach, further contributing to its earnings. The company's global presence, with a strong foothold in markets across Japan, the Americas, Europe, and Asia, also plays a crucial role in its revenue generation.
Astellas Pharma Financial Statement Overview
Summary
Astellas Pharma shows strong revenue growth and effective cost management, with a notable increase in net profit margin. The balance sheet is solid, with improved leverage ratios and financial flexibility, though operational efficiency could be enhanced. Robust cash flow generation underscores strong liquidity, supporting future growth.Income Statement
Astellas Pharma demonstrates strong revenue growth with a 19.22% increase from 2024 to 2025. The gross profit margin remains high at 74.57% for 2025, indicating effective cost management. The net profit margin improved significantly from 1.06% in 2024 to 2.65% in 2025. However, the EBIT margin slightly decreased to 13.37% in 2025, suggesting potential challenges in operational efficiency. Overall, the company shows strong growth and profitability trends.―
Balance Sheet
Astellas Pharma maintains a solid equity base with an equity ratio of 45.32% in 2025. The debt-to-equity ratio improved to 0.55, reflecting a decrease in leverage and financial risk. Return on Equity (ROE) increased to 3.35% in 2025, indicating better utilization of shareholders' equity. Despite the improvements, the relatively low ROE suggests there is room for enhancing shareholder value.76
Cash Flow
The company exhibits robust cash flow generation, with a free cash flow growth rate of 82.95% from 2024 to 2025. The operating cash flow to net income ratio is 3.97, reflecting strong cash flow relative to net income. The free cash flow to net income ratio is 3.24, indicating effective conversion of profits into cash. These metrics highlight Astellas Pharma's strong liquidity and financial flexibility.―
| Breakdown | ||||
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 1.60T | 1.52T | 1.30T | 1.25T | 1.30T | Gross Profit |
| 1.31T | 1.23T | 1.04T | 1.00T | 1.02T | EBIT |
| 124.61B | 133.03B | 155.69B | 136.05B | 243.99B | EBITDA |
| 195.34B | 240.46B | 241.03B | 219.83B | 316.41B | Net Income Common Stockholders |
| 17.05B | 98.71B | 124.09B | 120.59B | 195.41B |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 335.69B | 396.62B | 337.28B | 331.69B | 327.85B | Total Assets |
| 3.57T | 2.46T | 2.33T | 2.27T | 2.32T | Total Debt |
| 1.01T | 200.01B | 212.74B | 278.26B | 413.33B | Net Debt |
| 670.03B | -176.83B | -103.24B | -47.86B | 94.94B | Total Liabilities |
| 1.97T | 948.56B | 872.09B | 887.51B | 1.03T | Stockholders Equity |
| 1.60T | 1.51T | 1.46T | 1.39T | 1.29T |
| Cash Flow | Free Cash Flow | |||
| 89.98B | 239.23B | 181.00B | 229.40B | 144.11B | Operating Cash Flow |
| 172.47B | 327.77B | 257.44B | 306.84B | 222.00B | Investing Cash Flow |
| -845.80B | -84.50B | -62.41B | -81.89B | -389.79B | Financing Cash Flow |
| 614.06B | -195.62B | -216.30B | -229.48B | 181.06B |
Astellas Pharma Technical Analysis
Positive
1458.00
Price Trends
1404.28
Positive
1442.48
Positive
1544.65
Negative
Market Momentum
8.45
Negative
61.12
Neutral
85.27
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4503, the sentiment is Positive. The current price of 1458 is above the 20-day moving average (MA) of 1354.95, above the 50-day MA of 1404.28, and below the 200-day MA of 1544.65, indicating a neutral trend. The MACD of 8.45 indicates Negative momentum. The RSI at 61.12 is Neutral, neither overbought nor oversold. The STOCH value of 85.27 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4503.
Astellas Pharma Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Performance Comparison
JP:4503
Astellas Pharma
1,458.00
-33.22
-2.23%
CHGCF
Chugai Pharmaceutical Co
62.23
29.08
87.72%
DNPUF
Sumitomo Dainippon Pharma Co
6.53
4.05
163.31%
ESALF
Eisai Co
29.60
-11.57
-28.10%
SGIOF
Shionogi & Co
15.20
-0.40
-2.56%
TKPHF
Takeda Pharmaceutical Co
30.55
4.81
18.69%
Astellas Pharma Earnings Call Summary
Earnings Call Date:Apr 25, 2025
(Q4-2024)
| % Change Since: 7.17%|
Next Earnings Date:Jul 30, 2025
Earnings Call Sentiment Positive
Astellas Pharma demonstrated strong financial performance with record-breaking revenue and significant growth in Strategic Brands. Successful cost optimization and a positive outlook for FY 2025, including increased dividends and progress in primary focus programs, highlight a positive trajectory. Despite challenges such as the impact of U.S. Medicare Part D redesign and temporary demand issues with IZERVAY, the overall sentiment remains optimistic.Q4-2024 Updates
Positive Updates
Record-Breaking Revenue and Growth
In FY 2024, Astellas Pharma reported record high revenue of ¥1.912 trillion, a 19.2% increase year-on-year, and core operating profit of ¥392.4 billion, up by 41.7% year-on-year.
Strategic Brands Driving Growth
Sales of Strategic Brands, including PADCEV, IZERVAY, VEOZAH, VYLOY, and XOSPATA, exceeded ¥340 billion, more than doubling with a growth of ¥180 billion or 110% year-on-year.
Cost Optimization Success
Astellas Pharma achieved its cost optimization target of ¥40 billion in FY 2024, improving the SG&A ratio by 3.1 percentage points year-on-year.
Strong Outlook for FY 2025
Astellas expects continued strong momentum in Strategic Brands with projected revenue of ¥1.930 trillion and underlying growth excluding Forex impact expected to be 7%.
Dividend Increase
Astellas increased its dividend per share to ¥78, an increase of ¥4, in anticipation of future profit growth.
Primary Focus Program Progress
ASB-3082 achieved proof of concept (PoC) in pancreatic ductal adenocarcinoma, marking a significant milestone in targeted protein degradation.
Negative Updates
Impact of U.S. Medicare Part D Redesign
The redesign led to a gross-to-net impact on XTANDI sales in the U.S., although volume growth offset some of this impact.
IZERVAY Temporary Demand Slowdown
IZERVAY experienced a temporary demand slowdown due to a complete response letter (CRL) for label update submission, impacting growth.
Tariff and Forex Risks
The company acknowledged potential risks related to tariffs and Forex, although specific impacts were not disclosed.
Company Guidance
During the FY 2024 financial results announcement by Astellas Pharma Inc., several key financial metrics were highlighted, indicating a record year for the company. Revenue reached ¥1.912 trillion, marking a 19.2% increase year-on-year, while core operating profit rose by 41.7% to ¥392.4 billion. The company achieved significant growth in its Strategic Brands, with sales exceeding ¥340 billion, reflecting a growth of ¥180 billion or 110% year-on-year. The core operating profit margin improved by 3.3 percentage points to 20.5%. Astellas also reported substantial cost optimization, achieving a target of ¥40 billion, which improved the SG&A ratio by 3.1 percentage points. The Forex impact positively contributed ¥68.1 billion to revenue and ¥15.1 billion to core operating profit. Looking forward, Astellas forecasts further growth in FY 2025, with expected revenue of ¥1.930 trillion and a core operating profit increase to ¥410 billion, driven by continued expansion in Strategic Brands and ongoing cost optimization efforts.Astellas Pharma Corporate Events
Astellas Pharma Reports Higher Than Expected Financial Results
Apr 25, 2025
Astellas Pharma reported an increase in other income due to changes in the fair value of contingent consideration related to its clinical development plans and program discontinuations. The company’s actual financial results for the fiscal year ended March 31, 2025, exceeded forecasts, with significant increases in operating profit and profit before tax, reflecting strong operational performance.
FDA Approves Extended Use of Astellas’ IZERVAY for Geographic Atrophy
Feb 12, 2025
Astellas Pharma announced the FDA’s approval of an expanded label for IZERVAY™ for geographic atrophy secondary to AMD, allowing dosing beyond 12 months. The decision is based on positive results from the GATHER2 Phase 3 trial, which show IZERVAY’s efficacy in slowing GA progression. This approval strengthens IZERVAY’s market position, with significant distribution growth since 2023, and reaffirms its safety profile. The impact on Astellas’ financials for the fiscal year ending March 31, 2025, is expected to be minor.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.